Catalyst Pharmaceuticals (CPRX) to Release Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.53 per share and revenue of $130.86 million for the quarter.

Catalyst Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ CPRX traded down $0.50 during mid-day trading on Monday, hitting $24.34. The company had a trading volume of 263,255 shares, compared to its average volume of 1,100,599. The firm has a 50-day simple moving average of $22.84 and a two-hundred day simple moving average of $22.33. The company has a market capitalization of $2.97 billion, a PE ratio of 20.64, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals has a one year low of $14.47 and a one year high of $26.16.

Insiders Place Their Bets

In other news, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CPRX. HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Bank of America reaffirmed a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Robert W. Baird boosted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Finally, StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.